Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet

Journal of Clinical Pharmacology

Volumn 47, Issue 12, 2007, Pages 1521-1531

  Schwartz, Jules I ^a   Thach, Chau ^a   Lasseter, Kenneth C ^b   Miller, Jutta ^a   Hreniuk, David ^a   Hilliard, Deborah A ^a   Snyder, Karen M ^a   Gertz, Barry J ^a   Gottesdiener, Keith M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Clinical Pharmacology Associates Miami   (United States)

Author keywords

Blood pressure; Celecoxib; Etoricoxib; Naproxen; Sodium excretion

Indexed keywords

11 OXOTHROMBOXANE B2; 2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; CELECOXIB; CREATININE; ELECTROLYTE; ETORICOXIB; NAPROXEN; PLACEBO; PROSTACYCLIN; SODIUM; THROMBOXANE;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FUNCTION; MALE; MULTICENTER STUDY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; SODIUM BALANCE; SODIUM RESTRICTION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

6-KETOPROSTAGLANDIN F1 ALPHA; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; BODY WEIGHT; CONSTIPATION; CREATININE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROLYTES; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; NAPROXEN; POTASSIUM; PROSTAGLANDINS; PYRAZOLES; PYRIDINES; SODIUM; SULFONAMIDES; SULFONES; THROMBOXANE B2;

EID: 36148942413     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007307878     Document Type: Article

References (30)

1. Harris RC Jr. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol. 2002 ; 89: 10D - 17D.
2. Gertz BJ, Krupa D., Bolognese JA, Sperling RS, Reicin A. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Curr Med Res Opin. 2002 ; 18: 82-91.
3. Curtis SP, Ng J., Yu Q., et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther. 2004 ; 26: 70-83.
4. Schwartz JI, Vandormael K., Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther. 2002 ; 72: 50-61.
5. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med. 2000 ; 133: 1-9.
6. Murray MD, Lazaridis EN, Brizendine E., et al. The effect of nonsteroidal antiinflammatory drugs on electrolyte homeostasis and blood pressure in young and elderly persons with and without renal insufficiency. Am J Med Sci. 1997 ; 314: 80-88.
7. Nietert PJ, Ornstein SM, Dickerson LM, Rothenberg RJ Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. Pharmacotherapy. 2003 ; 23: 1416-1423.
8. Toto RD, Anderson SA, Brown-Cartwright D., Kokko JP, Brater DC Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney Int. 1986 ; 30: 760-768.
9. Ylitalo P., Pitkajarvi T., Pyykonen M-L., et al. Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol. Clin Pharmacol Ther. 1985 ; 38: 443-449.
10. Catella-Lawson F., McAdam B., Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999 ; 289: 735-741.
11. Rossat J., Maillard M., Nussberger J., Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999 ; 66: 76-84.
12. Matsumoto AK, Cavanaugh PF Jr. Etoricoxib. Drugs Today (Barc). 2004 ; 40: 395-414.
13. Committee on Diet and Health (National Research Council). Diet and Health: Implications for Reducing Chronic Disease Risk. Washington, DC: National Academy Press ; 1989: 414.
14. CELEBREX capsules (celecoxib). Groton, CT: Pfizer ; 2005. PDR Electronic Library. Available at: http://www.thomsonhc.com/pdrel/librarian. Accessed July 27, 2007.
15. ARCOXIA (etoricoxib). White House Station, NJ: Merck ; 2004. Available at: www.emea.eu.int/pdfs/human/referral/etoricoxib/EN%20Etoricoxib.pdf. Accessed July 27, 2007.
16. Naproxen. Nutly, NJ: Roche ; 2005. PDR Electronic Library. Available at: http://www.thomsonhc.com/pdrel/librarian. Accessed July 27, 2007.
17. Cockroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16: 31-41.
18. Wong P., Mukhopadhyay S., Quan H., Larson P. Confidence Intervals for Between-Treatment Mean Difference When Analysis Is on the Log Percent Scale. Alexandria, Va: American Statistical Association, Proceedings of the Biopharmaceutical Section ; 1999 :111-116.
19. Mulkerrin EC, Clark BA, Epstein FH Increased salt retention and hypertension from non-steroidal agents in the elderly. Q J Med. 1997 ; 90: 411-415.
20. Jaffe EA, Weksler BB Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest. 1979 ; 63: 532-535.
21. Zewde T., Mattson DL Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension. 2004 ; 44: 424-428.
22. Hao CM, Breyer MD Hypertension and cyclooxygenase-2 inhibitors: target: the renal medulla. Hypertension. 2004 ; 44: 396-397.
23. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 ; 368: 1771-1781.
24. Brater DC Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med. 1999 ; 107: 65S - 71S.
25. McAdam BF, Catella-Lawson F., Mardini IA, Kapoor S., Lawson JA, FitzGerald GA Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999 ; 96: 272-277.
26. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 1983 ; 67: 1174-1177.
27. Flavahan NA Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci. 2007 ; 28: 106-110.
28. Kawka DW, Ouellet M., Hetu PO, Singer II, Riendeau D. Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium. Biochim Biophys Acta. 2007 ; 1771: 45-54.
29. Dallob A., Hawkey CJ, Greenberg H., et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol. 2003 ; 43: 573-585.
30. Van Hecken A., Schwartz JI, Depré M., et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 ; 40: 1-12.